Abstract Library

#4528 Serum visfatin concentration in metastatic pancreatic and midgut NETs: An exploratory study

Introduction: Neuroendocrine tumours (NETs) are commonly diagnosed at advanced stages due to their diverse and often asymptomatic clinical presentation. Visfatin, an adipocytokine involved in regulating cellular energy homeostasis, inflammation, and tumorigenesis, has been investigated as a potential biomarker in several neoplasms. However, its role in NETs remains unexplored.

Conference:

Presenting Author:

Authors: Komarnicki P, Maciejewski A, Musiałkiewicz J, Mastorakos G, Gut P,

Keywords: visfatin, biomarker, nicotinamide phosphoribosyltransferase, NAMPT, PBEF, eNAMPT,

#4229 Bone health in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are a heterogeneous group of rare neoplasms, classified according to localization of the primary tumor, differentiation and grading. The effect of localized or advanced NENs and systemic therapies on bone and muscle health is still controversial.

Conference:

Presenting Author:

Authors: Casabella A, Veresani A, Boschetti M, Sulli A, Hasballa I,

Keywords: Bone health, neuroendocrine neoplasm, TBS, RSMI, T-Score,

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4110 The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT

Introduction: Renal impairment due to renal fibrosis is a potential side effect in NET-patients undergoing Peptide Receptor Radionuclide Therapy (PRRT). Fibrosis markers are small collagen formation - and degradation fragments that are measurable in circulation at very early stages of fibrosis formation.

Conference:

Presenting Author: Lau T

Authors: Lau T, Bossen L, Rasmussen D, Karsdal M, Genovese F,

Keywords: PRRT, Biomarker, Fibrosis Marker,

#4081 The risk of venous thromboembolism in neuroendocrine neoplasms: A single center experience

Introduction: Neuroendocrine Neoplasms (NENs) are a very heterogeneous group of tumors. Venous thromboembolism (VTE) is a common complication in cancer patients and one of the leading causes of mortality. There is a lack of data regarding the incidence and the impact of VTE in patients with NENs.

Conference:

Presenting Author: Belabdi D

Authors: Belabdi D, Bala N, Bouferoum L, Ou M,

Keywords: Neuroendocrine neoplasm, Venous thromboembolism,